Trials / Active Not Recruiting
Active Not RecruitingNCT06550895
A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
A Phase 2, Open-Label, Multicenter Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to define the safety of Ciltacabtagene Autoleucel (Cilta-cel) and Talquetamab in participants with high-risk multiple myeloma (MM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cilta-cel | Cilta-cel infusion will be administered intravenously. |
| DRUG | Talquetamab | Talquetamab will be administered subcutaneously. |
Timeline
- Start date
- 2024-09-16
- Primary completion
- 2026-08-31
- Completion
- 2027-08-26
- First posted
- 2024-08-13
- Last updated
- 2026-04-14
Locations
9 sites across 2 countries: United States, Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06550895. Inclusion in this directory is not an endorsement.